Related Experiment Video
Updated: Jul 15, 2026

Mapping Infant Immunity with Minimal Input: Integrative Single-Cell and Multiomic Profiling
Published on: April 3, 2026
Plasma soluble CD30 level correlates negatively with age in children
Jung Yu Chen1, Lin Shien Fu, Jao Jia Chu
1Division of Immunology, Rheumatology and Allergy, Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.
Insights
CD30 is not a reliable marker for atopic diseases in children, as its levels do not differ between atopic and non-atopic groups. Soluble CD30 (sCD30) levels inversely correlate with age in both groups.
Area of Science:
- Immunology
- Pediatric Allergy
Background:
- Atopic diseases are linked to immune dysregulation, specifically T helper cell type 1/2 (Th1/Th2) imbalances.
- CD30 is hypothesized as a marker for Th2-mediated immunity.
Purpose of the Study:
- To evaluate CD30 as a marker for atopy and Th2 immune predominance in children.
- To investigate the relationship between CD30 expression and atopic status in a pediatric cohort.
Main Methods:
- Assessed surface CD30 expression on T and B lymphocytes in 61 children with atopy and 27 controls.
- Measured plasma soluble CD30 (sCD30) levels in the same participants.
Main Results:
- No significant differences were observed in surface CD30 expression on lymphocytes between atopic and control children.
- Plasma sCD30 levels did not differ between the atopic and control groups.
- A strong negative correlation between sCD30 levels and age was found in both control (r = -0.72) and atopic (r = -0.45) children.
Conclusions:
- CD30 is not a suitable surrogate marker for atopic disease or Th2 immune responses in children.
- Age is a significant factor influencing sCD30 levels and must be considered in future research.
Background And Purpose:
Atopic diseases are thought to be associated with cytokine-mediated immune dysregulation, for example, a T helper cell type 1/2 (Th1/Th2) imbalance. CD30 is proposed to be one of the surrogate markers for Th2 immunity. In this study, we investigated whether CD30 is a good marker for atopy and Th2 predominance in a pediatric population.
Methods:
This study included 61 children with atopy and 27 normal controls. The expression of CD30 on the surface of T and B lymphocytes and soluble CD30 (sCD30) in plasma was determined.
Results:
There was no difference in the surface expression of CD30 on B or T lymphocytes. Similarly, sCD30 levels in plasma were not different between the 2 groups. Nevertheless, we found a strong negative correlation between sCD30 and age in the control group (r = -0.72, p<0.001; sCD30 = 76.1 - 5.18 x age) as well as in the atopy group (r = -0.45, p<0.01; sCD30 = 61.1 - 3.56 x age).
Conclusions:
An inverse relationship was found between age and sCD30 level in children. However, our findings suggest that CD30 is not a good marker for atopic disease and that further studies on sCD30 levels must take age into consideration.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacodynamics in Geriatric Patients: Effects of Age
